LEGN
Legend Biotech Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +12 | 61.78M | $1.78B | +17 | −5 |
| Q1 2026 | 82 | -3 | 51.41M | $929.52M | +5 | −8 |
| Q4 2025 | 86 | +2 | 50.21M | $1.09B | +2 | n/a |
| Q3 2025 | 13 | -2 | 38.53M | $1.26B | n/a | −2 |
| Q2 2025 | 12 | -1 | 34.51M | $1.22B | +1 | −2 |
| Q1 2025 | 10 | 0 | 13.38M | $453.85M | n/a | n/a |
| Q4 2024 | 10 | -1 | 15.80M | $514.13M | n/a | −1 |
| Q3 2024 | 10 | +3 | 16.52M | $804.74M | +3 | n/a |
| Q2 2024 | 7 | n/a | 18.35M | $812.58M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 11.49M | n/a | $508.86M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 2.81M | n/a | $124.43M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | Millennium Management ✦ | 1.66M | n/a | $73.46M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.44M | n/a | $63.99M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 477.53K | n/a | $21.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 304.52K | n/a | $13.49M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Bridgewater Associates ✦ | 165.46K | n/a | $7.33M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 189 holders, 95.78M shares, $1.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 27.37K sh · $258,920
Officer · 5.43K sh · $49,630
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology